

Johnson & Johnson Bets $3.3 Billion on Experimental Eye Disease Treatment
On November 16, 2026, Johnson & Johnson agreed upon a deal with Ollin Biosciences to acquire the company for a massive $3.3 billion. Johnson & Johnson is interested in Ollin’s treatments for eye diseases. However, this pipeline is still in an experimental phase and has yet to receive regulatory approval, signifying that J&J is taking a large risk with this investment. Regarding the deal itself, J&J will pay $2.2 billion upfront, while the remainder will arrive in payments dep
Evan Wang
26 minutes ago2 min read


America's Housing Market Hits a 16-Year Low as Mortgage Rates Squeeze Buyers
America’s housing market has slid to a halt as it reaches its slowest pace in over 16 years. This is driven by increased mortgage rates and rising home prices, which are decreasing the number of people willing to buy in today’s market. The National Association of Realtors stated that existing-home sales have dropped 5.5% in October to a seasonally adjusted rate of 3.75 million—the lowest level since 2010. Sales were also down 8.8% compared to the same period in 2025. The pri
Evan Wang
15 hours ago2 min read


Pfizer Secures $1.5 Billion From Blackstone to Compete in the Obesity Drug Market
Pharmaceutical giant Pfizer is receiving a major investment to fuel its advancements in the fast-growing obesity market. Blackstone Life Sciences agreed to provide funding of $1.5 billion to assist Pfizer’s development of berobenatide, a drug designed for weight loss. Pfizer seeks to utilize this funding in efforts to compete against other powerhouses like Eli Lilly and Novo Nordisk to secure dominance within the weight-loss industry. Berobenatide is a GLP-1 receptor agonist
Evan Wang
2 days ago2 min read


Nvidia’s $600 Billion Crisis: What Jensen Huang’s Exit Means for the AI Giant
In a recent turn of events that has shocked the world, Nvidia’s newest and biggest challenge yet may have nothing to do with technology. On November 12, 2026, Nvidia CEO Jensen Huang announced his resignation from the company. Following the discovery of his affair involving a woman with suspected ties to Chinese intelligence, the company that has led the revolution in artificial intelligence and is widely regarded as the powerhouse of technology has been under enormous press
Evan Wang
5 days ago2 min read


$2.5 Trillion Wiped From Nasdaq as AI Stocks Plunge
On November 5, the Nasdaq Composite fell 5.5%, wiping out a whopping $2.5 trillion in market value from the Nasdaq-100. The cause? Rapidly increasing doubt among investors over the future of artificial intelligence investments. This decline was Nasdaq’s worst day since April 2025 and pushed the index into correction territory, which happens when a stock market index falls over 10% from its peak. Taking part in this loss were some of the largest technology companies, like Nvi
Evan Wang
Nov 82 min read


Novartis' Heart Drug Fails Major Clinical Trial, Threatening $900 Million Partnership
On November 7, Novartis, a massive pharmaceutical company, released its phase 3 clinical trial results for pelacarsen, an experimental cardiovascular drug. Headlining the outcome was its failure to prevent serious cardiovascular events, even though it reduced a major cholesterol-related risk marker by nearly 78%. This setback doesn’t just affect Novartis, but raises concerns about all emerging therapies for heart disease and their commercial potential. Additionally, the failu
Evan Wang
Nov 72 min read
